whereas criteria based on a high cutoff were met later ( Fig. 1 , E and F). Marker kinetics with fast and medium rate constants were less influenced by background fluctuations.
The false-positive signals denoted TPA progression among events where TPA fluctuated in a steady state without any rate of increase (0.0000). The frequency and time point of the false-positive TPA signals were determined by the magnitude of the normal background fluctuations because larger fluctuations promoted the required critical difference. The criteria in Fig. 1 , E and F, did not give any false-positive progression signals when the concentrations fluctuated in the middle of the normal range. Their robustness against false-positive signals of progression was therefore further investigated in situations where TPA concentrations fluctuated closely below the applied cutoff value. Indeed, both criteria provided false progression signals if steady-state concentrations fluctuated high within the normal range. However, the criterion in Fig. 1F gave false-positive signals at unusually large clinical fluctuations, whereas the criterion in Fig. 1E also gave false signals at small fluctuations. The criterion in Fig. 1F was robust against false-positive progression signals, owing to a higher cutoff value. In reviewing the data provided in Table 1 , we believe it is clear that the criterion by Sölétormos et al. (3 ) (Fig. 1F) , which adjusted the cutoff value and the critical difference to the higher background variation of TPA, performed better than criteria by other authors where this issue was left unconsidered (4 -6 ) ( Table 1) . However, the importance of adjusting the algorithm to the individual marker also applied to the criteria elaborated by Sölétormos et al. (8 ) because the criteria that sufficed for CA 15.3-CEA (Fig. 1 , B and C) gave false positives when applied to TPA data (Table 1) . Conversely, the criteria that gave delayed CA 15.3-CEA information was more suitable for TPA ( Fig. 1F ; Table 1 ) (8 ) .
In conclusion, the elaborated computer-simulation models have considerable potential because criteria can be compared in a variety of simulated conditions of steady-state and progressive disease. Varying the background variation and the tumor growth according to realistic patient data, as well as the cutoff value, enabled identification of criteria that were robust against falsepositive signals of TPA progression. When data that define steady-state variability and rates of increase become available, the model systems should be used to generate assessment criteria for other markers and malignancies and compare and optimize diagnostic performance of the criteria. However, it is important to emphasize that computer-simulation studies cannot replace clinical tumor-marker trials. Computer-based comparison of assessment criteria is a supplement to clinical studies and relevant only if these studies have provided reliable estimates of basic performance characteristics. However, by simulating a large variety of new trial conditions, the robustness of a criterion can quickly be investigated at low costs, and a determination can be made as to whether the criterion is of limited use or should be implemented in routine clinical practice for patient monitoring. The plasma homocysteine concentration (tHcy) is affected by genetic and physiologic determinants, by life-style (including nutritional deficiencies of vitamins B 6 , B 12 , and folate), diseases, and by some drugs (1) (2) (3) (4) . Moderately increased tHcy is considered an independent risk factor for atherosclerotic disease in the coronary, cerebral, and peripheral arteries (1, 2 ) and a significant predictor of mortality in patients with coronary disease (5, 6 ) . In renal and cardiac transplant recipients, tHcy is markedly increased and is associated with impaired renal function (7) (8) (9) (10) (11) (12) and with low serum folate in some series (8 -11 ) . Some studies (7, 10 ) , but not others (8, 11, 12 ) , have reported that cyclosporine treatment and whole blood cyclosporine concentration were determinants of tHcy in renal and cardiac transplant recipients. Data on tHcy in liver transplant recipients are limited, and increased tHcy has been associated with renal dysfunction but not with folate concentrations or cyclosporine therapy (13 ) .
Determinants of Increased Plasma
Our aims were to evaluate the prevalence of increased Clinical Chemistry 47, No. 11, 2001 tHcy and factors that affect tHcy in liver transplant patients. We studied 221 consecutive patients with clinically stable liver transplants seen between November 1999 and May 2000 at routine clinic visits. There were 141 men and 80 women. The immunosuppressive therapy for all patients was cyclosporine or tacrolimus. Twenty-five patients were also treated with mycophenolate, nine with azathioprine, and one with prednisone. Hypocaloric diets had been recommended for patients with diabetes and obesity, and alcohol abstention had been recommended for all patients. The patients who had received transplants Ͻ12 months before the study were excluded. Healthy volunteers (n ϭ 50) with prudent lifestyles made up the control group, which included staff members of the University Hospital (Madrid, Spain) or their relatives. Controls were age-and sex-matched with the patients. Patients and controls who were being treated at the time of this study with drugs that could alter tHcy were excluded.
We evaluated age, sex, time since transplant, body mass index [(BMI); kg/m 2 ], smoking (any cigarette smoking in the past month) (14 ) , presence of diabetes, hypertension, cardiovascular disease, immunosuppressive therapy, tHcy, serum creatinine, albumin and bilirubin, creatinine clearance, serum folate, vitamin B 12 , and fasting (overnight) lipoprotein concentrations. Obesity was defined as BMI Ն30 kg/m 2 . Hypertension was defined as systolic blood pressure Ն140 mmHg and/or diastolic blood pressure Ն90 mmHg more than two times during the preceding year, or the need for antihypertensive treatment. Hypercholesterolemia was defined as a fasting LDLcholesterol concentration Ն3.4 mmol/L or the need for antilipemic agents. Diabetes was defined as a fasting plasma glucose Ն7.0 mmol/L on 2 different days during the year before the study or the need for antidiabetic agents. Cardiovascular disease was defined as coronary disease (myocardial infarction), cerebrovascular disease (transient ischemic episode and/or thrombotic stroke), or peripheral vascular disease (occlusive or subocclusive artery disease and/or abdominal aorta aneurysm). tHcy was determined by fluorescence polarization immunoassay (15 ) . Blood collected in Vacutainer Tubes (Termo Europe N.V.) containing EDTA was immediately placed on ice and centrifuged within 1 h after collection at 1200g for 5 min. Plasma was stored frozen at Ϫ20°C until analysis. We defined increased tHcy as Ͼ2 SD above the mean of the controls; tHcy concentrations in controls showed a normal distribution.
Vitamin B 12 and serum folate were determined by RIA (SimulTRAC-SNB; ICN Pharmaceuticals). Serum creatinine, albumin, and bilirubin were measured on a Hitachi 747-200 analyzer (Roche). Creatinine clearance was estimated from the formula of Cockcroft and Gault (16 ) . Lipoproteins were isolated by ultracentrifugation (17 ) ; cholesterol and triglycerides in the fractions were assayed enzymatically. Whole blood cyclosporine was determined by RIA (Incstar) and whole blood tacrolimus by fluorescence polarization immunoassay (Abbott).
The local ethical committee approved the protocol, and informed consent was obtained from all participants.
Means comparisons of continuous numeric variables were tested by the Student t-test. Categorical variables were tested by the 2 test. Associations between continuous variables were assessed by Pearson coefficients. P Ͻ0.05 was considered significant. Multiple linear regression analysis (backward) was used to evaluate the relationship between tHcy and the independent variables age, sex, serum creatinine, folate and vitamin B 12 concentrations, and treatment with cyclosporine or tacrolimus. A logistic regression analysis (outcome variable, increased tHcy: yes/no) was performed to determine the association between increased tHcy and the same independent variables.
Mean Creatinine concentration was higher and creatinine clearance lower in patients compared with controls (P Ͻ0.001), as well as in patients on cyclosporine compared with those on tacrolimus therapy (P Ͻ0.001). Further details regarding the control and patient clinical characteristics and the patients on cyclosporine or tacrolimus therapy are available in an on-line supplement at Clinical Chemistry Online (http://www.clinchem.org/content/ vol47/issue11). tHcy was increased in 103 patients (47%). It was more prevalent in men, in older patients, in patients treated with cyclosporine, and in those with hypertension (Table  1) , but in all these cases, creatinine concentration was more increased (P Յ0.001). Increased tHcy was not more prevalent in smokers or patients with obesity, diabetes, hypercholesterolemia, or a longer time since transplant (Table 1) . Pearson correlation showed that tHcy was correlated with age (r ϭ 0.20; P ϭ 0.003), creatinine concentration (r ϭ 0.62; P ϭ 0.0001), creatinine clearance (r ϭ Ϫ0.53; P ϭ 0.0001), and folate concentration (r ϭ Ϫ0.24; P ϭ 0.0008). There was no correlation between tHcy and time since transplant, BMI, serum albumin, bilirubin, lipoproteins, vitamin B 12 , or whole blood cyclosporine and tacrolimus concentrations.
A multiple linear regression showed that only creatinine (r 2 ϭ 0.35; P ϭ 0.0001) and folate (r 2 ϭ 0.04; P ϭ 0.0006) were independent predictors of tHcy, after simultaneous adjustment for age, sex, vitamin B 12 concentration, and cyclosporine or tacrolimus treatment. A logistic regression also showed that increased tHcy was associated with creatinine (odds ratio, 150; 95% CI, 29 -785) and folate concentrations (odds ratio, 0.86; 95% CI, 0.76 -0.98).
Other cardiovascular risk factors (smoking, obesity, diabetes, hypertension, and hypercholesterolemia) were also found in a high percentage of the patients (see on-line data supplement). Eight cardiovascular events occurred in 7 patients (coronary disease in 2, cerebrovascular disease in 2, and peripheral arterial disease in 4) between 13 and 84 months after transplantation [mean, 37 months; mean patient age, 56 Ϯ 6 years (range, 50 -66 years), mean (SD) tHcy, 16.7 (5.6) mol/L]; and 5 patients had increased tHcy.
A previous study (13 ) showed a lower prevalence (27%) of increased tHcy in liver transplant patients, but did not indicate whether patients were on treatments that could decrease tHcy (e.g., vitamins) or increase it (e.g., methotrexate, anticonvulsants, theophylline, trimethoprim-sulfamethoxazole, bile acid-binding resins, and fibrates). Renal function was the main predictor of tHcy in the present study, with 35% of the variability of tHcy explained by creatinine. A moderate increase of tHcy is almost always observed in renal insufficiency (18 ) , but the etiology is not well understood. A relationship with impaired intrarenal homocysteine metabolism has been proposed (19 ) , although an extrarenal defect in its metabolism can be another contributory factor (20 ) .
In the present series, tHcy was higher in patients on cyclosporine treatment compared with tacrolimus treatment. However, creatinine and prevalence numbers of several other known confounders of tHcy were also higher in cyclosporine-treated patients (see on-line data supplement). Multivariate analysis, which included creatinine, showed no association between tHcy and cyclosporine therapy, an observation consistent with other studies (8, 11, 12 ) . The influence of cyclosporine on renal function is well known, and it is possible that a potential influence of cyclosporine on tHcy may be conferred by impaired renal function. Ignatescu et al. (21 ) recently showed that cyclosporine had no influence on homocysteine export from human renal proximal tubular epithelial cells. Their findings do not support the concept that cyclosporine directly increases tHcy in transplant patients.
Folate concentrations were associated with tHcy in our study, but explained only 4% of tHcy variability. A negative association between tHcy and folate has been described in renal and cardiac transplant recipients (8 -11 ) , but not in liver recipients. There was no association between vitamin B 12 concentration and tHcy. This could be attributable to the fact that the great majority of the patients were not vitamin B 12 deficient, a fact that may be related to the relatively young age of the study population. Folate supplementation with or without the addition of vitamin B 12 and/or B 6 decreases tHcy in renal and liver transplant patients, even in the absence of folate deficiency (12, 13, 22, 23 ) . Although some researchers recommend treatment of increased tHcy with vitamin supplements in patients with coronary disease or multiple cardiovascular risk factors (24 ) , the preventive effect of such therapy still remains to be determined. Randomized trials are currently under way (25 ) .
In renal transplant recipients, increased tHcy may be associated with increased risk of cardiovascular disease (8, 26 ) , a major complication in these patients (27 ) . In liver transplant recipients, atherosclerotic disease has not been considered as an important problem (28 -30 ) . A recent large study of these patients (31 ), however, found that cardiovascular and cerebrovascular diseases were the second most important cause of late graft loss. In our study, atherosclerotic disease was present in only seven patients (3%); all were Ն50 years of age. This complication increases with the age of the liver transplant recipients (30 ) . Our series included rather young participants, 38% of whom were Ͻ50 years, which could explain the low incidence of cardiovascular events. The high prevalence of high tHcy and other cardiovascular risk factors suggests the need for careful follow-up for atherosclerotic disease.
In summary, increased tHcy is frequently found in liver transplant patients. The prevalence of increased tHcy is even higher in patients treated with cyclosporine compared with those undergoing tacrolimus treatment. It remains unclear whether cyclosporine directly affects homocysteine metabolism or whether increased tHcy may be attributable to impaired renal function or higher prevalence of other confounders in these individuals. Serum creatinine is the most important predictor of tHcy, whereas serum folate had only minor influence. Avoidable, unhealthy lifestyle factors (e.g., smoking and obesity) and associated diseases (e.g., diabetes, hypertension, and hypercholesterolemia) did not influence tHcy significantly in our study. Methylmalonic acidemias (MMAs) and propionic acidemias (PAs) comprise a group of congenital disorders of branched-chain amino acid metabolism (1 ). PA is caused by deficiency of propionyl-CoA carboxylase, whereas MMA results from deficiency of either methylmalonylCoA mutase or defects in the production of adenosylcobalamin. Deficiency of vitamin B 12 , a cofactor for methylmalonyl-CoA mutase, will also produce signs and symptoms consistent with MMA (2-4 ) . Other biochemically closely related disorders are the cobalamin (Cbl) defects, classified as forms A through G (5 ). Clinical signs and symptoms include failure to thrive, metabolic acidosis, persistent ketotic episodes, hypoglycemia, hypotonia, hyperammonemia, and neurologic symptoms (6 ) . Children with PA, MMA, or Cbl disorders often present with acute illness as neonates or infants. Treatment of MMA and PA includes careful monitoring and limitation of branched-chain amino acid intake (4 ) as well as possible
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